Document is current
Any future updates will be listed below
-
Authors
Rosarda, Jessica D. https://orcid.org/0000-0002-2742-7413
Giles, Sarah
Harkins-Perry, Sarah
Mills, Elizabeth A.
Friedlander, Martin https://orcid.org/0000-0003-4238-9651
Wiseman, R. Luke https://orcid.org/0000-0001-9287-6840
Eade, Kevin T. https://orcid.org/0000-0003-3371-6016
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (AG046495, RFNS125674)
Lowy Medical Research Institute
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 23 June 2023
First Online: 11 July 2023
Competing interests
: R.L.W. is an inventor on patents describing ATF6-activating compounds (e.g., AA147) and IRE1/XBP1s activating compounds (e.g., IXA4). R.L.W. is a board member and shareholder in Protego Biopharma who has licensed IRE1/XBP1 and ATF6-activating compounds for translational development. All other authors declare no competing interests.
